

**Minutes of the December 12, 2014
Pharmacy & Therapeutics (P&T) Committee Meeting
South Dakota Department of Social Services, Division of Medical Services**

Members present

Bill Ladwig, RPh; Dana Darger, RPh; James Engelbrecht, MD; Lenny Petrik; Deb Farver; Kelley Oehlke

DSS staff present

Mike Jockheck, RPh

Administrative business

The P&T meeting was called to order by D. Darger at 1:00pm. The minutes of the September 26, 2014 meeting were presented. D. Farver made a motion to approve. K. Oehlke seconded the motion. The motion was approved unanimously.

Prior authorization update and statistics

The committee reviewed the prior authorization (PA) activity for October 2014. There were a total of 3,409 PA's processed in the month of October, with 99.35% of those requests responded to in less than eight hours. There were 2,581 (76%) requests received electronically and 828 (24%) requests received by fax.

Analysis of the top 15 therapeutic classes

The committee reviewed the Top 15 therapeutic classes by total cost of claims from 07/1/2014 – 09/30/2014. The top five classes were antipsychotics, respiratory and CNS stimulants, central nervous system agents, misc., amphetamines, and insulins. The top 15 therapeutic classes make up 40.30% of total claims. The Committee also reviewed the top 25 drugs based on total claims cost and number of claims. The top 25 drugs by claims cost make up 9.38% of total claims.

Review of drug spend

The committee reviewed a table showing SD Medicaid drug spend from 2012 – 2014. The average cost per script rose from \$64.45 in 2012 to \$77.33 in 2014. The average recipient script cost rose from \$172.76 in 2012 to \$209.07 in 2014.

Patent expirations

The committee reviewed a list of medications with an upcoming anticipated availability of a first-time generic.

Hepatitis C update

The committee reviewed Harvoni, Solvadi, and Olysio PA forms with incorporated changes since the last meeting. Utilization for the new medications used to treat Hepatitis C was provided. Brent Hildebrand, representing Gilead spoke regarding Harvoni.

Stimulant use in adults

The committee reviewed stimulant use in adults at the September meeting. It was requested that a form be developed for stimulant use in adults. After reviewing the form provided, the committee recommended removing 'specialist involved in therapy' and adding a check box for concomitant benzos/opioids. A motion was made by J. Engelbrecht to make recommended changes to the ADHD for adults form. B. Ladwig seconded the motion. The updated form will be brought to the March meeting.

Evzio review

The committee reviewed the prior authorization form provided for Evzio. B. Ladwig made a motion to approve the form. D. Farver seconded the motion. The motion was approved unanimously.

Otezla review

The committee reviewed the prior authorization form provided for Otezla. J. Engelbrecht made a recommendation that 'specialist involved in therapy' be added as well as a request for patient's GFR. Kendig Bergstresser, representing Celgene, spoke regarding Otezla. J. Engelbrecht made a motion to make modifications to the form and table until March. D. Farver seconded the motion. The motion was approved unanimously. The Otezla form will be brought back to the March meeting.

High cost medications

The committee reviewed the prior authorization form for high cost medications. There was no public comment. B. Ladwig made a motion to approve the form. K. Oehlke seconded the motion. The motion was approved unanimously.

GLP-1 receptor agonists review

The committee reviewed GLP-1 clinical information. There was no public comment. J. Engelbrecht made a motion to place GLP-1 receptor agonists on prior authorization. L. Petrick seconded the motion. The motion was approved unanimously. The prior authorization form for GLP-1 receptor agonists will be brought back to the March meeting.

New topical therapies for onychomycosis review

The committee reviewed topical therapies for onychomycosis clinical information. There was no public comment. J. Engelbrecht made a motion to place these agents on prior authorization. D. Farver seconded. A form will be brought back to the March meeting.

The next meeting is scheduled for March 20, 2015. B. Ladwig made a motion to adjourn the P&T Committee meeting. D. Farver seconded the motion. The motion passed unanimously and the meeting was adjourned.